Case Study: Managing Cardiovascular Risk in a Diabetic Patient with Mixed Dyslipidemia
2.00 AMA PRA Category 1 Credits™, 2.00 AANP, 2.00 ANCC
Learning Objective
Participants should be able to outline treatment strategies to effectively manage patients with type 2 diabetes and mixed dyslipidemia.
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 2.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 2.00 |
AANP |
Pri-Med Institute is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308. |
This program has been approved for 2 contact hours of continuing education, which includes 1 hours of pharmacology. |
| 2.00 |
ANCC |
Pri-Med Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. |
This activity for 2 contact hours is provided by Pri-Med Institute. |
Faculty and Editorial Board
Written By:
Michael H. Davidson, MD, FACC, FACP, (Read Bio), Clinical Professor, Director, Preventive Cardiology, Associate Vice Chairman, Continuing Medical Education, The University of Chicago Pritzker School of Medicine, Executive Medical Director, Radiant Research, Chicago, IL
Reviewed By:
Tufts University Medical School
Edited By:
Jean Baker, MS, RD
Financial Disclosure Statement(s)
Dr Davidson receives grant/research support, honorarium or serves as a consultant/speaker for the following companies: Abbott Laboratories, Merck/Schering-Plough, AcademicCME, Omthera, AstraZeneca Pharmaceuticals, Professional Evaluation, Inc., Daiichi-Sankyo, Inc., Roche Pharmaceuticals, diaDexus, Inc., sanofi-aventis, GlaxoSmithKline, Sonogene, Kinemed, Synarc, LipoScience, Takeda Pharmaceuticals, Merck & Co., Inc., Vindico.
Ms Baker has no financial relationships to disclose.
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
